oncolyt
viru
therapi
base
abil
virus
effect
infect
kill
tumor
cell
without
destroy
normal
tissu
virus
seem
natur
prefer
tumor
cell
virus
requir
modif
tropism
specif
enter
replic
cell
review
aim
describ
transduct
target
strategi
current
employ
specif
redirect
virus
toward
surfac
receptor
tumor
cell
three
major
strategi
distinguish
involv
incorpor
new
target
specif
viral
surfac
protein
ii
incorpor
scaffold
viral
surfac
protein
allow
attach
target
moieti
iii
use
bispecif
adapt
mediat
target
viru
specifi
moieti
tumor
cell
strategi
key
featur
advantag
limit
discuss
exampl
given
potenti
caus
sustain
multiround
infectiona
desir
characterist
erad
tumorsparticular
attent
given
virus
engin
becom
selftarget
genom
express
bispecif
adapt
protein
cancer
one
major
health
problem
time
though
prognosi
peopl
diagnos
least
form
cancer
increas
consider
typic
diseas
treatment
initi
effect
follow
later
irrevers
eventu
fatal
relaps
alreadi
decad
cancer
treatment
base
three
type
approach
surgeri
radio
chemotherapi
scientif
technolog
advanc
improv
efficaci
classic
approach
tremend
also
new
therapi
evolv
includ
immunotherapi
treatment
appar
fail
erad
residu
tumor
cell
metastas
complet
therefor
addit
mean
urgent
requir
support
replac
convent
therapi
henc
varieti
new
approach
current
explor
one
base
use
virus
oncolyt
virus
defin
abil
specif
kill
tumor
cell
leav
normal
tissu
unharm
characterist
featur
thu
target
specif
cytolyt
capac
ideal
exhibit
addit
featur
includ
limit
high
reproduct
capac
vivo
abil
recruit
uninfect
neighbor
cell
syncytia
format
abil
infect
divid
nondivid
cell
high
stabil
vivo
inabl
chromosom
integr
lack
diseas
induct
gener
absenc
preexist
antibodi
viru
host
popul
infect
cell
virus
primarili
depend
success
entri
cell
first
step
virusbind
cell
reli
specif
interact
viral
attach
protein
cellular
receptor
virus
natur
prefer
replic
tumor
cell
acquir
tropism
serial
passag
cell
cultur
cell
exampl
includ
measl
viru
mump
viru
newcastl
diseas
viru
recent
review
vesicular
stomat
viru
reoviru
mani
virus
howev
lack
mean
select
bind
tumor
cell
epitop
adapt
virus
oncolyt
therapi
advanc
virolog
natur
tropism
need
alter
allow
bind
tumorspecif
receptor
approach
call
transduct
target
review
outlin
recent
develop
transduct
target
virus
focu
three
strategi
retarget
virus
seem
promis
develop
new
oncolyt
virus
section
review
strategi
virus
could
success
provid
new
tropism
introduc
target
inform
one
viral
surfac
protein
strategi
investig
activ
limit
overview
exampl
virus
new
target
specif
could
genom
encod
section
approach
describ
scaffoldbas
modif
viral
surfac
protein
appli
direct
virion
new
target
cell
includ
use
biotin
antibodybind
moieti
section
review
use
bispecif
adapt
protein
mediat
bind
virion
tumor
cell
often
adapt
simpli
combin
respect
virus
therebi
enabl
singleround
infect
case
target
devic
incorpor
genet
viru
gener
selftarget
agent
abl
independ
spread
tumor
final
review
complet
gener
conclus
current
statu
field
oncolyt
virotherapi
view
futur
popular
approach
gener
oncolyt
virus
adapt
surfaceexpos
compon
viral
surfac
protein
modifi
express
ligand
bind
receptor
preferenti
exclus
express
tumor
cell
virus
genet
adapt
express
modif
redirect
toward
tumor
cell
figur
b
main
advantag
strategi
target
specif
inher
viral
genom
thu
maintain
upon
replic
progeni
viru
abl
infect
neighbor
cell
harbor
target
receptor
therebi
establish
multiround
infect
maintain
tumor
target
cell
remain
strategi
abil
genet
modifi
viral
genom
crucial
furthermor
detail
structur
inform
viral
surfac
protein
modifi
indispens
predict
locat
target
motif
might
toler
expos
motif
allow
bind
modifi
virion
cell
also
detriment
entri
mechan
particular
viru
interf
instanc
fusion
viral
cellular
membran
addit
target
ligand
introduc
viral
protein
meet
size
limit
small
peptid
thu
seem
first
obviou
choic
develop
target
strategi
virus
howev
sever
limit
shortag
natur
exist
molecul
avail
use
target
ligand
therefor
sourc
bind
ligand
investig
incorpor
viral
protein
purpos
includ
part
antibodi
like
scfv
singlechain
variabl
fragment
compos
fusion
variabl
region
heavi
v
h
light
chain
v
l
immunoglobulin
fab
antigenbind
fragment
compos
one
constant
one
variabl
domain
heavi
light
chain
antibodi
feasibl
modifi
viral
coat
protein
demonstr
number
virus
summar
adenovirus
among
extens
studi
virus
oncolyt
viral
therapi
wildtyp
infect
adenovirusbind
cell
mediat
major
attach
factor
fiber
protein
via
carboxi
termin
knob
domain
protein
bind
primari
cellular
receptor
coxsackieadenoviru
receptor
car
follow
viral
attach
intern
mediat
interact
rgd
motif
penton
base
cellular
integrin
order
achiev
carindepend
infect
adenovirus
viral
tropism
modifi
via
genet
engin
adenoviru
capsid
protein
list
review
describ
develop
genet
redirect
adenovirus
incorpor
ligand
viral
surfac
protein
numer
summari
heterolog
peptid
ligand
success
engin
mani
adenovir
protein
includ
hi
loop
fiber
c
terminu
fiber
loop
hexon
rgd
loop
penton
base
minor
capsid
protein
ix
commonli
target
moieti
insert
hi
loop
fiber
knob
protein
import
insert
site
ligand
demonstr
introduc
model
peptid
cdcrgdcfc
knob
insert
ligand
three
five
analyz
loop
knob
still
allow
trimer
knob
protein
result
adenovirus
show
superior
infect
virus
peptid
fuse
fiber
c
terminu
precis
ligand
posit
pivot
demonstr
lack
enhanc
infect
ligandflank
linker
extend
tandem
copi
ligand
peptid
insert
interestingli
also
antibodybas
target
could
achiev
adenovirus
gener
fiber
chimera
fusion
scfv
capsid
protein
ix
recent
review
transduct
target
adenovirus
reader
refer
adenovirus
possibl
combin
transduct
transcript
target
increas
adenovir
specif
make
group
virus
particularli
interest
futur
therapi
howev
strong
immunogen
natur
might
serious
hamper
efficaci
vivo
measl
viru
anoth
viru
well
studi
oncolyt
therapi
attenu
measl
viru
strain
edmonston
abil
select
destroy
neoplast
tissu
review
measl
viru
two
envelop
glycoprotein
hemagglutinin
h
attach
protein
fusion
f
protein
viru
attach
entri
subsequ
cellcel
fusion
mediat
via
two
measl
receptor
signal
lymphocyt
activ
molecul
slam
improv
specif
infect
tumorspecif
ligand
introduc
ctermin
extens
h
protein
rang
ligand
includ
peptid
scfv
toler
addit
allow
redirect
viru
cell
express
appropri
viru
receptor
natur
ligand
pivot
thu
though
length
linker
separ
v
h
v
l
domain
import
scfv
incorpor
virion
certainli
affect
membran
fusion
abil
viru
review
redirect
measl
viru
pleas
see
edmonston
strain
use
vaccin
year
safeti
profil
impress
might
provid
good
basi
futur
applic
oncolyt
therapi
anoth
field
activ
studi
involv
use
herp
simplex
viru
tumor
therapi
review
herpesviru
infect
cell
attach
heparan
sulfat
proteoglycan
mediat
viral
glycoprotein
gc
gb
follow
interact
glycoprotein
gd
one
two
altern
protein
receptor
one
design
herpesviru
entri
mediat
member
famili
tumor
necrosi
factor
receptor
second
involv
intercellular
adhes
molecul
belong
immunoglobulin
ig
superfamili
retarget
hsv
could
achiev
insert
ligand
scfv
gc
andor
gd
protein
subsequ
increas
infect
target
cell
express
appropri
viru
receptor
current
strategi
redirect
hsv
toward
tumor
cell
recent
review
anoth
herpesviru
gamma
herp
viru
saimiri
nativ
bind
region
viral
glycoprotein
heparan
sulphat
replac
peptid
sequenc
interact
somatostatin
receptor
known
overexpress
hepatocellular
carcinoma
cell
subsequ
recombin
viru
appear
infect
carcinoma
cell
well
wildtyp
viru
show
reduc
infect
cell
line
reason
observ
unclear
conclus
herpesvirus
remain
promis
candid
oncolyt
therapi
redirect
tumor
cell
consid
reason
safe
due
induct
selflimit
diseas
human
hand
wide
natur
tropism
presenc
viral
antibodi
human
popul
might
hamper
effect
vivo
less
frequent
studi
candid
develop
oncolyt
agent
aav
review
aav
broad
host
cell
rang
due
widespread
distribut
primari
cellular
receptor
heparan
sulfat
proteoglycan
viral
capsid
protein
respons
interact
host
cell
receptor
transduct
target
independ
nativ
tropism
could
demonstr
genet
incorpor
target
peptid
six
differ
put
loop
capsid
protein
result
show
mutant
capsid
effici
incorpor
three
mutant
express
capsid
surfac
one
effici
infect
wildtyp
cell
line
express
integrin
receptor
recogn
import
incorpor
site
peptid
sequenc
elucid
studi
show
assembl
gener
infecti
particl
abil
transduc
target
cell
depend
posit
capsid
ligand
introduc
success
target
demonstr
toward
rgd
toward
human
lutein
hormon
receptor
due
broad
cell
tropism
wildtyp
aav
retarget
combin
ablat
natur
tropism
remain
crucial
develop
viru
safe
oncolyt
vector
replicationcompet
retrovirus
gain
interest
oncolyt
agent
particular
high
transduct
effici
review
mulv
differ
class
distinguish
host
rang
base
interact
envelop
glycoprotein
particular
cell
surfac
receptor
ecotrop
mulv
particularli
capabl
infect
mous
rat
cell
amphotrop
mulv
infect
rang
mammalian
includ
human
cell
via
wide
express
receptor
initi
studi
redirect
ecotrop
mulv
toward
human
tumor
cell
point
toward
import
interact
envelop
glycoprotein
origin
viru
receptor
despit
correct
fold
chimer
envelop
glycoprotein
display
scfv
incorpor
viral
particl
bind
pseudotyp
viru
particl
carri
chimer
ecotrop
env
human
cell
result
virus
infecti
target
cell
review
expand
studi
use
amphotrop
mulv
target
infect
could
achiev
incorpor
high
molecular
weight
melanomaassoci
antigen
hmwmaa
target
toward
egf
igf
folat
receptor
unsuccess
despit
observ
bind
cell
express
receptor
propos
traffick
viru
particl
lysosom
subsequ
degrad
caus
lack
infect
attempt
overcom
problem
insert
transloc
domain
exotoxin
pseudomona
aeruginosa
envelop
protein
order
transloc
virion
endosom
cytoplasm
unsuccess
clearli
choic
receptor
ultim
import
success
target
retroviru
vector
toward
tumor
cell
vaccinia
viru
studi
antitumor
properti
alreadi
long
time
despit
entri
wide
rang
cell
sever
vaccinia
viru
strain
natur
prefer
replic
cancer
tissu
report
ident
natur
receptor
still
debat
like
involv
wide
express
surfac
compon
like
heparan
sulfat
chondroitin
sulfat
proteoglycan
tumor
target
improv
delet
vaccinia
viru
gene
necessari
replic
normal
cell
cancer
cell
recent
review
increas
specif
tropism
tumorspecif
scfv
display
surfac
vaccinia
viru
particl
target
moieti
introduc
fuse
scfv
direct
tumorassoci
antigen
nterminu
nonessenti
hemagglutinin
ha
protein
vaccinia
viru
strain
ihdj
similarli
nonessenti
membraneassoci
protein
vaccinia
strain
mva
could
replac
fusion
molecul
carri
insert
scfv
direct
tumorassoci
antigen
result
fusion
protein
could
express
expos
envelop
recombin
viru
abl
bind
target
cell
preferenti
infect
target
cell
howev
observ
like
recombin
mhv
virus
encod
mutat
protein
modifi
protein
presenc
wild
type
spike
protein
gener
target
recombin
indic
whether
intend
recombin
virus
could
actual
isol
confirm
rtpcr
sequenc
also
indic
tropism
success
gener
recombin
viru
murin
human
cell
verheij
rottier
unpublish
data
recombin
virus
still
contain
wildtyp
host
cell
attach
protein
provid
infect
broad
cell
rang
therefor
futur
challeng
transduct
target
vaccinia
viru
toward
tumor
cell
lie
elimin
natur
tropism
favor
characterist
ofparticularli
nonhumancoronavirus
potenti
oncolyt
agent
recogn
recent
virus
spike
protein
respons
receptor
bind
subsequ
cell
entri
viruscel
membran
fusion
aminotermin
domain
requir
virusbind
cell
undergo
order
structur
chang
domain
mediat
fusion
cell
membran
infect
cell
coronavirus
depend
express
specif
cellular
receptor
make
virus
highli
speciesspecif
exampl
entri
mhv
mediat
murin
carcinoembryon
antigen
receptor
attempt
redirect
coronavirus
particular
mhv
mutat
viral
surfac
protein
unsuccess
incorpor
ligand
rgd
ngr
variou
nonconserv
domain
domain
spike
protein
appear
toler
select
retarget
recombin
virus
base
new
bind
properti
modifi
spike
success
figur
verheij
rottier
unpublish
data
obvious
without
much
knowledg
tertiari
structur
coronaviru
spike
protein
conform
chang
cell
entri
chanc
high
introduct
even
small
ligand
affect
proper
function
mhv
strain
carri
accessori
hemagglutininesteras
surfac
glycoprotein
attempt
also
use
glycoprotein
retarget
equal
unsuccess
though
gene
modif
insert
small
peptid
ligand
termin
extens
antiegfr
could
incorpor
viral
genom
result
recombin
virus
unabl
redirect
mhv
human
tumor
cell
figur
verheij
rottier
unpublish
data
rather
incorpor
specif
tumor
target
inform
viral
surfac
protein
altern
approach
involv
incorpor
scaffold
moieti
protein
subsequ
variou
type
target
modul
link
schemat
depict
figur
c
main
strateg
differ
rel
previou
method
moieti
incorpor
tumor
ligand
repres
attach
site
exogen
provid
target
moieti
besid
advanc
virolog
scaffold
also
bind
receptor
interest
compar
figur
b
c
essenti
oper
limit
target
strategi
provid
virus
establish
singleround
infect
remain
depend
extern
suppli
target
modul
yet
advantag
flexibl
target
devic
bind
alway
previous
modifi
viral
protein
chang
rel
easi
strategi
base
antibodi
target
give
opportun
redirect
oncolyt
viru
virtual
everi
tumor
surfac
epitop
particular
applic
base
principl
reli
biotin
strept
avidincoupl
method
review
adenovirus
singleround
target
viru
particl
could
gener
use
biotinstreptavidin
coupl
system
incorpor
biotinacceptor
peptid
fiber
metabol
biotinyl
adenoviru
coupl
egfstreptavidin
complex
found
success
infect
egfr
express
target
cell
similarli
biotinpolyethylen
glycol
peg
egf
conjug
coupl
avidinmodifi
adenoviru
could
redirect
viru
nonn
receptor
anoth
studi
small
protein
ligand
capabl
select
bind
human
igg
iga
incorpor
model
ligand
tropismmodifi
adenovirus
viabl
virus
genet
incorpor
scaffold
fiber
gene
could
rescu
incub
antibodi
abl
enter
cell
display
fc
receptor
surfac
recent
demonstr
specif
chemoselect
modif
adenovir
particl
could
also
function
scaffold
target
devic
metabol
incorpor
noncanon
monosaccharid
amino
acid
adenovir
particl
conjug
folat
target
motif
combin
taxoid
achiev
initi
result
demonstr
increas
toxic
vitro
viru
igbind
fragment
protein
test
possibl
scaffold
redirect
aav
fragment
success
introduc
capsid
protein
provid
versatil
platform
antibodymedi
aav
target
recent
studi
biotinacceptor
peptid
incorpor
aav
particl
subsequ
biotin
label
virus
biotin
ligas
bira
attach
rgd
peptid
target
integrin
result
signific
increas
transduct
endotheli
cell
demonstr
feasibl
approach
sindbi
viru
inher
oncolyt
properti
studi
quit
extens
oncolyt
viru
review
one
surfac
protein
mammalian
cell
mediat
sindbi
viru
infect
laminin
receptor
overexpress
variou
human
tumor
envelop
protein
sindbi
viru
respons
receptor
bind
increas
specif
infect
research
combin
introduct
ligand
viral
envelop
use
target
molecul
end
viru
particl
gener
contain
iggbind
domain
protein
insert
envelop
protein
combin
antibodi
bound
specif
surfac
antigen
nonsuscept
cell
chimer
viru
abl
infect
otherwis
refractori
cell
compar
combin
approach
taken
introduc
igbind
domain
ntermin
extens
glycoprotein
ad
speciesmatch
antibodi
fc
receptorposit
cell
line
could
success
infect
also
mlv
studi
perform
introduc
iggbind
domain
protein
enabl
modular
use
antibodi
variou
specif
vector
target
insert
bind
domain
hing
region
viral
envelop
protein
virion
gener
capabl
captur
antibodi
subsequ
effici
bind
virusantibodi
complex
target
cell
enhanc
transduct
cell
observ
use
bispecif
adapt
adapt
eleg
strategi
current
employ
target
virus
toward
tumor
cell
make
use
bispecif
adapt
protein
consist
two
domain
arm
one
bind
virion
cell
surfac
epitop
interest
therebi
enabl
indirect
interact
viru
tumor
cell
composit
adapt
protein
vari
greatli
depend
design
arm
virusbind
domain
use
includ
solubl
receptor
fragment
socal
pseudoreceptor
polym
like
peg
part
antibodi
includ
scfv
fab
moieti
appli
cellbind
natur
peptid
vitamin
ligand
receptor
scfv
fab
direct
cell
epitop
interest
specif
two
differ
antigen
achiev
either
join
arm
togeth
chemic
combin
two
moieti
one
fusion
protein
often
flexibl
linker
target
arm
typic
cterminu
principl
redirect
virus
toward
nonn
cell
use
bispecif
protein
shown
figur
typic
exampl
two
domain
depict
figur
b
tabl
overview
provid
combin
arm
bispecif
adapt
protein
actual
gener
target
virus
tumor
cell
target
use
adapt
redirect
virus
toward
tumor
cell
sever
advantag
introduct
target
scaffold
moieti
viral
attach
protein
first
detail
structur
inform
requir
viral
surfac
protein
manipul
protein
requir
second
size
target
part
adapt
protein
seem
less
crucial
introduc
moieti
viral
protein
choic
target
easili
expand
use
part
antibodi
way
select
target
receptor
becom
virtual
tabl
ligand
peptid
adenoviru
unlimit
antibodi
gener
rel
easi
receptor
interest
identifi
third
adapt
protein
straightforward
construct
expand
repertoir
target
receptor
becom
rel
easi
final
bind
adapt
protein
virion
least
case
report
ablat
viru
natur
tropism
especi
use
oncolyt
viru
choic
prefer
normal
cell
host
also
disadvantag
use
bispecif
protein
target
oncolyt
virus
bispecif
protein
artifici
polypeptid
compos
part
occur
link
togeth
natur
proper
biogenesi
advanc
virolog
independ
fold
moieti
effici
secret
may
impair
moreov
unless
express
oncolyt
viru
product
purif
adaptor
challeng
redirect
oncolyt
virus
toward
tumor
cell
bispecif
protein
appli
two
way
first
recombin
product
chemic
synthesi
protein
precomplex
virion
appli
vitro
vivo
major
drawback
approach
howev
allow
singleround
infect
progeni
viru
abl
infect
neighbor
cell
amount
adapt
protein
limit
consequ
use
adapterprecomplex
virus
vivo
like
restrict
local
rather
system
applic
probabl
also
requir
repeat
administr
high
dose
adapt
protein
littl
known
potenti
risk
approach
altern
genet
inform
adapt
protein
incorpor
viral
genom
properli
express
ensur
local
product
target
devic
togeth
progeni
viru
infect
cell
approach
enabl
multiround
infect
later
spread
oncolyt
viru
time
span
henc
efficaci
kind
therapi
limit
emerg
immun
bispecif
protein
andor
viru
feasibl
strategi
depend
avail
genet
modif
system
introduc
adapterencod
gene
viral
genom
addit
express
cassett
modif
system
current
avail
virus
capac
genom
accept
insert
limit
henc
size
target
moieti
might
restrict
final
genet
stabil
recombin
virus
might
issu
particular
adapt
protein
use
ablat
natur
tropism
viru
feasibl
use
adapt
protein
oncolyt
viral
therapi
explor
number
virus
first
present
overview
studi
target
tumor
cell
perform
coadministr
virus
adaptor
protein
section
thereaft
discuss
studi
describ
genet
target
oncolyt
virus
gener
incorpor
gene
code
bispecif
protein
viral
genom
section
adenovirus
redirect
adenovirus
tumor
cell
neutral
antiknob
fiber
antibodi
use
extens
first
demonstr
potenti
applic
retarget
virus
nonadenoviru
cellular
receptor
antibodi
chemic
conjug
folat
shown
mediat
infect
folatereceptor
express
cell
mani
nonn
receptor
sinc
target
conjug
antiknob
antibodi
fragment
either
ligand
peptid
antibodi
domain
direct
cellular
receptor
result
success
target
toward
egf
receptor
egfr
fgf
receptor
integrin
also
known
epcam
melanomaassoci
antigen
hmwmaa
receptor
carbon
anhydras
ix
protein
variou
organand
tumor
home
peptid
receptor
mesothelin
msln
prostatespecif
membran
antigen
psma
receptor
similar
approach
explor
use
antibodi
direct
adenovir
protein
thu
fab
direct
penton
base
fiber
combin
target
ligand
egf
igf
could
mediat
infect
target
cell
express
appropri
receptor
also
fab
direct
hexon
protein
chemic
link
fab
specif
bind
antigen
highli
overexpress
human
hepatocellular
carcinoma
success
appli
redirect
adenovirus
nonn
receptor
anoth
strategi
success
employ
purpos
made
use
pseudoreceptor
approach
bispecif
protein
gener
fusion
solubl
form
car
scar
egf
fc
region
human
scfv
cea
yet
anoth
approach
polym
exploit
target
ligand
singl
round
fashion
adenoviru
particl
coat
inhibit
natur
tropism
ligand
includ
peptid
scfv
attach
sever
type
polym
use
includ
polyethylen
metacrylamid
deriv
success
target
adenovirus
rgd
receptor
propos
adenovir
coat
polym
might
enhanc
potenti
system
deliveri
prolong
viral
plasma
halfliv
reduc
hepatotox
vivo
final
anoth
type
bispecif
molecul
base
bind
abil
gla
domain
coagul
factor
x
hexon
exploit
target
upon
fusion
gla
scfv
protein
increas
infect
tumor
cell
adenoviru
could
observ
howev
anticip
reduct
liver
transduct
observ
adenoassoci
virus
aav
broad
host
cell
rang
due
widespread
distribut
primari
cellular
receptor
heparan
sulfat
proteoglycan
achiev
specif
infect
bispecif
fab
test
one
arm
recogn
cellsurfac
integrin
bound
aav
capsid
target
way
inhibit
downstream
step
requir
product
infect
moreov
decreas
infect
normal
permiss
cell
observ
indic
bispecif
protein
abl
ablat
normal
tropism
herpesvirusesherp
simplex
viru
hsv
bind
cell
mediat
sever
wide
express
cell
surfac
receptor
includ
hsv
success
redirect
egfr
mean
solubl
adapt
protein
compris
ntermin
domain
fuse
scfv
direct
advanc
virolog
egfr
adaptermedi
entri
howev
promot
presenc
heparan
sulfat
proteoglycan
cell
also
requir
wildtyp
hsv
infect
avian
paramyxoviru
ndv
hemagglutininneuraminidas
hn
protein
respons
sialic
acid
receptor
attach
f
protein
mediat
fusion
viral
envelop
cellular
membran
ndv
oncolyt
properti
natur
howev
broad
cell
tropism
due
widespread
occurr
sialic
acid
mani
cell
narrow
specif
use
bispecif
adapt
protein
investig
preincub
ndv
recombin
bispecif
protein
compos
scfv
hn
block
nativ
receptor
bind
site
peptid
clearli
enhanc
specif
viru
reduc
sideeffect
appli
system
vivo
felin
infecti
periton
viru
fipv
first
demonstr
retarget
coronavirus
achiev
exchang
viral
spike
ectodomain
thu
felin
mhv
fmhv
murin
fipv
mfipv
gener
murin
virus
carri
felin
ectodomain
vice
versa
otherwis
highli
speciesspecif
recombin
virus
abl
cross
speci
barrier
fmhv
acquir
felin
cell
tropism
complet
lost
murin
cell
tropism
opposit
true
mfipv
extend
speci
tropism
nonhuman
coronavirus
toward
human
tumor
cell
bispecif
adapt
protein
gener
protein
compos
bispecif
scfv
direct
felin
spike
protein
egfr
could
mediat
fipv
fmhv
infect
egfrexpress
human
cancer
cell
subsequ
syncytia
format
typic
product
coronaviru
infect
subsequ
studi
redirect
murin
coronaviru
mhv
human
tumor
cell
base
adapt
protein
consist
pseudoreceptor
compos
ntermin
domain
murin
solubl
receptor
sor
fuse
scfv
direct
egfr
egf
ligand
adapt
protein
could
mediat
egfrspecif
entri
mhv
human
cancer
cell
howev
contrast
mani
previou
exampl
ablat
natur
tropism
viru
observ
overcom
major
drawback
inher
singleround
target
number
investig
focus
express
bispecif
adapt
viral
genom
order
allow
recombin
virus
produc
target
devic
sustain
infect
feasibl
approach
far
demonstr
adenovirus
coronavirus
adenovirus
redirect
adenovirus
nonn
surfac
receptor
condit
replic
adenovirus
crad
seem
virus
choic
due
select
replic
tumor
cell
first
experi
demonstr
abil
redirect
crad
toward
tumor
cell
perform
use
dualviru
mixtur
consist
crad
adenoviru
secret
bispecif
adapt
protein
consist
fusion
solubl
car
receptor
egf
ligand
dual
viru
infect
result
increas
oncolyt
activ
vitro
improv
therapeut
efficaci
vivo
subsequ
crad
engin
express
bispecif
adapt
protein
van
beusechem
et
al
develop
crad
encod
bispecif
protein
compos
antiegfr
scfv
antifib
knob
scfv
result
viru
produc
bispecif
protein
replic
cancer
cell
yield
progeni
viru
enhanc
infect
oncolyt
properti
egfrposit
cardefici
tumor
cell
howev
addit
infect
mediat
egfr
viru
retain
capac
infect
cell
bind
nativ
receptor
car
integrin
abolish
nativ
tropism
mutat
introduc
elimin
car
integrin
bind
result
recombin
viru
strictli
egfrdepend
target
profil
reduc
replic
egfrneg
cell
virus
display
similar
oncolyt
potenc
cell
line
tissu
specimen
also
appli
mous
model
intrajugular
intramuscular
inject
nativ
tropism
adenovirus
appear
reduc
remov
car
integrinbind
site
strikingli
howev
express
solubl
caregf
target
moieti
crad
rather
dual
viru
system
oncolyt
potenti
sever
impair
suggest
express
biolog
activ
protein
counterproduct
viru
replic
overcom
biosynthet
differ
bispecif
protein
translat
secret
via
ergolgi
rout
adenoviru
translat
cytoplasm
assembl
nucleu
eleg
strategi
develop
tag
adenoviru
fiber
scfv
synthet
leucin
zipperlik
dimer
domain
tag
protein
zipper
peptid
sequenc
preserv
trimer
capabl
adenoviru
fiber
recognit
egfr
zipperscfv
protein
importantli
gave
rise
receptorspecif
infect
target
cell
sever
studi
shown
feasibl
use
bispecif
protein
redirect
adenovirus
toward
target
cell
ex
vivo
vivo
laboratori
anim
model
includ
although
quit
effect
studi
base
twocompon
strategi
requir
mix
virion
bispecif
protein
administr
knowledg
vivo
studi
yet
perform
use
recombin
adenovirus
express
bispecif
adapt
viral
genom
establish
whether
superior
target
cellkil
abil
coronavirus
gener
selftarget
coronavirus
initi
code
sequenc
bispecif
adapt
protein
compos
solubl
receptor
link
histag
incorpor
mhv
viral
genom
target
recombin
creat
virusdesign
mhvsorhi
presenc
addit
express
cassett
toler
result
recombin
virus
inde
express
adapt
protein
inocul
target
cell
express
artifici
hisreceptor
surfac
show
recombin
virus
abl
establish
multiround
receptordepend
infect
furthermor
extens
cellcel
fusion
rapid
cell
kill
infect
target
cell
observ
demonstr
possibl
gener
genet
redirect
coronavirus
express
cassett
subsequ
extend
insert
sequenc
encod
egf
peptid
solubl
receptor
histag
gener
recombin
mhvsoregfhi
therebi
acquir
abil
caus
multiround
infect
otherwis
nonsuscept
egfrexpress
cell
cultur
vitro
subsequ
effici
cytolyt
activ
importantli
redirect
viru
demonstr
oncolyt
capac
also
vivo
orthotop
xenograft
mous
model
surviv
rate
mice
significantli
longer
tumorbear
anim
treat
mhvsoregfhi
treatment
control
viru
mhvsorhi
pb
figur
none
mhvsoregfhi
treat
micerecurr
tumor
load
could
detect
demonstr
strong
oncolyt
capac
virus
vivo
figur
b
despit
impress
oncolyt
effect
vivo
redirect
mhv
replic
mhv
nontumor
tissu
natur
host
observ
figur
c
presum
natur
tropism
mhv
ablat
experi
demonstr
composit
bispecif
protein
critic
import
success
gener
recombin
oncolyt
coronavirus
particular
viabl
recombin
coronavirus
express
bispecif
scfv
addit
express
cassett
viral
genom
could
rescu
figur
verheij
rottier
unpublish
data
subsequ
introduct
bispecif
gene
encod
sor
fuse
scfv
egfr
gener
viabl
virus
howev
virus
genet
highli
unstabl
loos
foreign
gene
usual
alreadi
within
one
passag
figur
verheij
rottier
unpublish
data
success
incorpor
even
larger
foreign
gene
posit
mhv
genom
report
includ
exampl
geneencod
luciferas
instabl
scfv
like
due
particular
sequenc
composit
rather
size
conclus
oncolyt
coronavirus
express
solubl
receptor
ctermin
extend
peptid
ligand
great
potenti
oncolyt
therapi
expand
target
repertoir
exchang
peptid
ligand
coronavirus
probabl
redirect
toward
variou
tumor
epitop
provid
bind
fusion
abil
viral
protein
maintain
murin
coronavirus
display
great
speci
specif
infect
ablat
natur
tropism
probabl
requir
make
mhv
safe
candid
oncolyt
agent
use
mammal
includ
human
appeal
idea
oncolyt
virotherapi
may
realiz
still
disconcertingli
remot
overview
emphat
reveal
field
retarget
virus
therapeut
use
earli
infanc
fact
major
virus
studi
scientist
still
struggl
fundament
aspect
chang
cell
tropism
robust
platform
retarget
actual
establish
yet
virus
posit
side
feasibl
retarget
least
vitro
demonstr
increas
number
virus
past
year
clearli
attract
goal
gener
oncolyt
virus
carri
retarget
inform
genom
virus
abl
sustain
replic
tumor
tissu
irrespect
retarget
principl
use
whether
modif
viral
attach
protein
express
adapt
protein
howev
pre
clinic
data
efficacylet
alon
safetyof
transduct
target
virus
vivo
limit
one
except
transduct
transcript
target
adenoviru
none
genet
modifi
tropism
modifi
oncolyt
virus
enter
phase
clinic
trial
make
virtual
imposs
compar
virus
review
thu
mani
hurdl
yet
overcom
new
oncolyt
virus
reach
clinic
import
futur
task
challeng
field
summar
one
major
challeng
base
idea
oncolyt
virotherapi
avail
suitabl
target
receptor
tumor
cell
ideal
receptor
uniqu
highli
overexpress
order
provid
suffici
specif
infect
recent
develop
proteom
field
alreadi
recogn
variou
protein
overexpress
tumor
cell
compar
normal
tissu
mani
hope
identifi
remain
howev
question
whether
truli
uniqu
tumor
surfac
protein
exist
stress
need
increas
specif
oncolyt
virus
way
achiev
exampl
combin
transduct
target
either
transcript
target
attenu
viral
genom
increas
tumorspecif
replic
transcript
target
viral
gene
essenti
replic
place
control
tumorspecif
promoterwhich
particularli
feasibl
dna
virusesor
control
ire
element
case
rna
virus
attenu
viral
genom
might
achiev
delet
viral
gene
elimin
function
dispens
tumor
cell
normal
tissu
feasibl
combin
transduct
translat
target
alreadi
demonstr
dna
virus
includ
adenoviru
rna
virus
investig
rather
focu
transduct
target
attenu
virus
natur
tropism
therapeut
viru
anoth
aspect
need
taken
account
regard
safeti
ablat
nativ
tropism
might
requir
virus
natur
infect
human
prevent
infect
normal
tissu
also
viru
prefer
bind
instanc
blood
substanc
exhibit
hepat
tropism
major
caus
loss
infecti
viru
vivo
use
nonhuman
virus
oncolyt
therapi
gain
interest
virus
usual
nonpathogen
human
addit
preexist
antibodi
circul
might
limit
efficaci
howev
adapt
new
host
virus
might
also
pose
risk
review
order
achiev
effect
erad
tumor
cell
desir
characterist
oncolyt
virus
abil
caus
sustain
multiround
infect
achiev
figur
introduct
bispecif
adapt
cassett
coronavir
genom
schemat
represent
mhv
genom
bispecif
express
cassett
introduc
herein
plusstrand
rna
genom
contain
polymeras
precursor
gene
accessori
gene
gene
nonessenti
gene
gene
encod
virion
protein
e
n
recombin
virus
gene
cluster
replac
express
cassett
downstream
translat
regul
sequenc
protein
recombin
mhv
virus
gener
target
recombin
indic
whether
particular
recombin
viru
could
isol
confirm
rtpcr
viru
rna
addit
abil
virus
infect
murin
human
cell
depict
verheij
rottier
unpublish
data
abbrevi
adapt
specifi
text
na
applic
virus
genet
redirect
incorpor
tumorbind
ligand
incorpor
bispecif
adapt
viral
genom
stabil
recombin
virus
might
howev
matter
concern
particular
target
protein
requir
ablat
natur
human
tropism
gener
dna
virus
consid
stabl
rna
virus
addit
mutat
rate
rel
high
irrespect
origin
viru
immun
induc
upon
repeat
viral
treatment
viral
antigen
also
foreign
protein
like
bispecif
adapt
express
viral
genom
might
limit
effect
therapi
shield
virus
antibodi
polym
might
use
coat
virion
yet
might
compromis
bind
viru
tumor
cell
technic
perform
upon
applic
later
spread
viru
way
increas
deliveri
oncolyt
viru
tumor
cell
especi
appli
system
might
use
carrier
cell
abil
home
tumor
conclus
transduct
target
virus
may
provid
much
need
tumorspecif
therapi
research
face
besid
technolog
challeng
delic
balanc
safeti
effect
develop
new
virus
clinic
use
yet
despit
problem
concern
import
ultim
goal
win
fight
cancer
warrant
sacrific
energi
creativ
need
realiz
